中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2015年
9期
39-40,41
,共3页
美罗华%B细胞性非霍奇金淋巴瘤%化学治疗
美囉華%B細胞性非霍奇金淋巴瘤%化學治療
미라화%B세포성비곽기금림파류%화학치료
rituximab%B cell non-Hodgkin ’ s lymphoma%chemotherapy regimen
目的：观察利妥昔单抗(美罗华)单药或联合化学治疗（简称化疗）和单用CHOP方案治疗初治的B细胞性非霍奇金淋巴瘤( NHL )患者的临床疗效及不良反应。方法将纳入研究的85例患者依据用药方案的不同分为美罗华单药或联合化疗组（美罗华组）39例和CHOP组46例，观察近期疗效及不良反应，并随访2年观察生存情况。结果美罗华组完全缓解率为84.62%，明显高于CHOP组的54.35%（ P＜0.05）；美罗华组总有效率为94.87%，明显高于CHOP组的63.04%（ P＜0.05）；治疗后随访2年，美罗华组1年生存率为79.49%、2年生存率为69.23%，CHOP组分别为65.21%和36.96%，两组1年生存率比较无显著性差异（ P＞0.05），2年生存率则有显著性差异（ P＜0.05）；两组不良反应发生率及严重程度比较，无显著性差异（ P＞0.05）。结论美罗华联合化疗治疗初治的B细胞性NHL疗效更佳，且未增加不良反应，值得临床推广。
目的：觀察利妥昔單抗(美囉華)單藥或聯閤化學治療（簡稱化療）和單用CHOP方案治療初治的B細胞性非霍奇金淋巴瘤( NHL )患者的臨床療效及不良反應。方法將納入研究的85例患者依據用藥方案的不同分為美囉華單藥或聯閤化療組（美囉華組）39例和CHOP組46例，觀察近期療效及不良反應，併隨訪2年觀察生存情況。結果美囉華組完全緩解率為84.62%，明顯高于CHOP組的54.35%（ P＜0.05）；美囉華組總有效率為94.87%，明顯高于CHOP組的63.04%（ P＜0.05）；治療後隨訪2年，美囉華組1年生存率為79.49%、2年生存率為69.23%，CHOP組分彆為65.21%和36.96%，兩組1年生存率比較無顯著性差異（ P＞0.05），2年生存率則有顯著性差異（ P＜0.05）；兩組不良反應髮生率及嚴重程度比較，無顯著性差異（ P＞0.05）。結論美囉華聯閤化療治療初治的B細胞性NHL療效更佳，且未增加不良反應，值得臨床推廣。
목적：관찰리타석단항(미라화)단약혹연합화학치료（간칭화료）화단용CHOP방안치료초치적B세포성비곽기금림파류( NHL )환자적림상료효급불량반응。방법장납입연구적85례환자의거용약방안적불동분위미라화단약혹연합화료조（미라화조）39례화CHOP조46례，관찰근기료효급불량반응，병수방2년관찰생존정황。결과미라화조완전완해솔위84.62%，명현고우CHOP조적54.35%（ P＜0.05）；미라화조총유효솔위94.87%，명현고우CHOP조적63.04%（ P＜0.05）；치료후수방2년，미라화조1년생존솔위79.49%、2년생존솔위69.23%，CHOP조분별위65.21%화36.96%，량조1년생존솔비교무현저성차이（ P＞0.05），2년생존솔칙유현저성차이（ P＜0.05）；량조불량반응발생솔급엄중정도비교，무현저성차이（ P＞0.05）。결론미라화연합화료치료초치적B세포성NHL료효경가，차미증가불량반응，치득림상추엄。
Objective To observation the clinical efficacy and adverse reactions of rituximab monochemotherapy or combination chemotherapy and single CHOP regimen in the initial treatment of B cell non-Hodgkin ’ s lymphoma. Methods 85 cases of B cell non-Hodgkin ’ s lymphoma were included in this study and divided into the rituximab chemomonotherapy or combination chemotherapy group ( rituximab group, 39 cases ) and the CHOP group ( 46 cases ) . The short term efficacy and adverse reactions of the two groups were observed, and the survival situation was observed for 2-year follow-up. Results The complete remission rate was 84. 62% in the rituximab group and 63. 04% in the CHOP group, the difference was statistically significant ( P < 0. 05 ) , the total effective rate was 94. 87% in the rituximab group and 54. 35% in the CHOP group, the difference was statistically significant ( P < 0. 05 );during 2-year follow-up after treatment, the 1-year survival rate and the 2-year survival rate in the rituximab group were 79. 49% and 69. 23%respectively, which in the CHOP group were 65. 21% and 36. 96% respectively, there was no statistically significant difference in the 1-year survival rate between the two groups ( P > 0. 05 ) , but there was statistically significant difference in the 2-year survival rate between the two groups ( P < 0. 05 );the occurrence rate and severity of adverse reactions had no in the statistically significant differ-ences between the two groups ( P > 0. 05 ) . Conclusion The rituximab combination chemotherapy in the initial treatment of B cell non-Hodgkin ’ s lymphoma has better efficacy without increasing the adverse reactions and should be expanded in application.
